SCHEMBL6133697

SCHEMBL6133697

CCCn1nc(-c2sc(C(=O)NC3CC3)nc2-c2ccccc2)ccc1=O

nearest known ligand 0.46

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
HSD17B10 Q99714 3/20 0.46
SMN1; SMN2 Q16637 2/20 0.45
USP2 O75604 2/20 0.44
MAPK1 P28482 1/20 0.44
TP53 P04637 1/20 0.44
CYP2D6 P10635 1/20 0.42
ALDH1A1 P00352 3/20 0.41
KDM4E B2RXH2 3/20 0.41
CNR1 P21554 3/20 0.41
CNR2 P34972 2/20 0.41
MEN1 O00255 2/20 0.40
KMT2A Q03164 2/20 0.40
MAPT P10636 2/20 0.40
HTT P42858 2/20 0.40
LMNA P02545 1/20 0.40
GAA P10253 1/20 0.40
PKM P14618 1/20 0.40
CYP1A2 P05177 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6133518 0.92 USP2 (0.46) HSD17B10SMN1; SMN2USP2MAPK1TP53
SCHEMBL6828616 0.91 USP2 (0.43) HSD17B10SMN1; SMN2USP2MAPK1CYP2D6
SCHEMBL6133653 0.88 ALDH1A1 (0.54) SMN1; SMN2USP2MAPK1ALDH1A1CNR1
SCHEMBL6133443 0.87 HSD17B10 (0.50) HSD17B10SMN1; SMN2USP2TP53CYP2D6
SCHEMBL6133434 0.87 ALDH1A1 (0.46) SMN1; SMN2MAPK1CYP2D6ALDH1A1KDM4E
SCHEMBL6920286 0.86 HTT (0.43) SMN1; SMN2USP2MAPK1CYP2D6ALDH1A1
SCHEMBL6133496 0.85 KDM4E (0.54) HSD17B10SMN1; SMN2USP2TP53KDM4E
SCHEMBL6133851 0.84 HSD17B10 (0.45) HSD17B10SMN1; SMN2USP2TP53KDM4E
SCHEMBL6133760 0.83 MAOB (0.40) SMN1; SMN2TP53ALDH1A1CNR1CNR2
SCHEMBL6133474 0.82 HTT (0.50) HSD17B10SMN1; SMN2TP53ALDH1A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050004134-A1 Thiazole derivative and pharmaceutical use thereof ASTELLAS PHARMA INC. (JP) 2005-01-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050004134-A1 Thiazole derivative and pharmaceutical use thereof MC2R, CYP2C9, OXTR HSD17B10 391/4885SMN1; SMN2 3135/4885USP2 4097/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.